Amneal Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) is a diversified, global biopharmaceutical leader focused on developing, manufacturing, and distributing high-quality, affordable, and innovative medicines. Founded in 2002 by brothers Chirag and Chintu Patel, the company operates through three distinct business segments: Affordable Medicines (retail generics, injectables, and biosimilars), Specialty (branded therapies primarily targeting central nervous system and endocrine disorders), and AvKARE (a repackaging and distribution business serving the U.S. federal government, retail, and institutional markets). Amneal maintains a robust global manufacturing and R&D footprint across the United States, India, and Ireland.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Acquiring 100% of Kashiv BioSciences to transition from a licensed commercialization model to a fully integrated global biosimilars developer and manufacturer.
Expected impact: Establishes in-house manufacturing with four facilities, scales drug substance capacity to 75,000 liters by 2028, and targets a portfolio of over 12 commercial products and 20+ pipeline assets by 2030.
Sustaining growth in the retail generics, injectables, and biosimilars segment by maintaining a high cadence of complex product launches.
Expected impact: Expected to drive 7% to 8% revenue growth in the Affordable Medicines segment in 2026, offsetting generic erosion in other areas.
Expanding the branded specialty portfolio, led by the Parkinson's disease therapy CREXONT, to offset the generic erosion of RYTARY.
Expected impact: CREXONT is expected to scale and drive the segment back to growth from 2027 onwards.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To secure in-house development and manufacturing infrastructure for biosimilars, transforming Amneal into a vertically integrated biologics player to capture the upcoming wave of blockbuster biologic patent expirations.
Financial impact: Expected to become accretive in 2027, driving projected total revenue growth of 7% to 13% in 2027 and supporting long-term 2030 revenue targets of $4.25 billion to $4.5 billion.
Strategic Partnerships
Collaboration for GLP-1 products to enter the high-growth weight loss and diabetes therapeutic space.
Terms: Not fully disclosed.
Secured exclusive U.S. commercialization rights to two denosumab biosimilars (referencing Prolia and Xgeva), which were FDA approved in December 2025.
Terms: mAbxience is responsible for full development and manufacturing, while Amneal retains exclusive U.S. commercialization rights.